Congestive Heart Failure: Major World Markets, Volume II: Devices (Pacemaker, ICD, LVAD and Artificial Heart Markets)

Congestive Heart Failure: Major World Markets, Volume II: Devices (Pacemaker, ICD, LVAD and Artificial Heart Markets)
Chapter one: Executive Summary
  • Background
  • Scope and Methodology
  • Size and Growth of Market

CHAPTER  TWO: OVerview of Congestive  Heart FailurE

  • Backgroun
  • Pathophysiolog
    • Types of Heart Failur
    • Left Ventricular (LV) Failure
    • Right Ventricular (RV) Failure
    • Systolic Dysfunction
    • Diastolic Dysfunction
    • High Output Failure
    • Theories of Congestive Heart Failure
    • Hemodynamic Response Theory
    • Neurohormonal Response Theory
    • Renal Response Theory
    • Conditions Leading to Congestive Heart Failure
    • Myocardial Infarction
    • Hypertension
    • Cardiomyopathy
    • Atrial Fibrillation
    • Other Risk Factor
    • Diagnosis of Congestive Heart Failure
    • Classification of Congestive Heart Failure Patients
    • Epidemiolog
    • United States
    • Europe
    • Japan

CHAPTER THrEE: Device Treatment of Congestive Heart Failure

  • Artificial Pacemaker
  • Ventricular Assist Devices (VADs)
  • Total Artificial Hearts (TAHs)
  • American College of Cardiology Guideline

CHAPTER FOUR: CONGEStive Heart Failure Patient ManagemenT

  • Guidelines for Management of Chronic Heart Failur
  • Strategies to Maintain Quality Patient Care and Contain Costs

CHAPTER FIVE: WORLD MARKETS

  • United States
  • Europe
  • Japan

CHAPTER  SIX: Company Profiles

  • Abbott Laboratories
  • Abiomed, Inc.
  • Ambu, USA
  • Aortech International, plc
  • Arrow International
  • Atrium Medical Corporation
  • ATS Medical, Inc.
  • Bacchus Vascular, Inc.
  • Berlin Heart AG
  • Biophan Technologies, Inc.
  • Biosensors International
  • Biotronik, Inc.
  • Boston Scientific
  • CardiacAssist, Inc.
  • Cardiac Science Corporation
  • Cardiogenesis Corporation
  • Cordis Corporation/Biologics Delivery Systems
  • CoreValve, Inc.
  • CryoCath Technologies, Inc.
  • Cryocor, Inc.
  • Datascope
  • Defibtech, LLC
  • Deltex Medical
  • Heartlab
  • Impulse Dynamics USA, Inc.
  • MedicalCV, Inc.
  • Medtronic, Inc.
  • Orqis Medical Corporation
  • Sorin SpA
  • Stereotaxis, Inc.
  • St. Jude Medical, Inc.
  • Teleflex Medical
  • Terumo Heart, Inc.
  • Thoratec Corporation
  • Ventracor, Inc.
  • Volcano Corporation

CHAPTER SEVEN: STRATEGIC CONCLUSIONS

  • First Conclusion
  • Second Conclusion
  • Implications:
  • Third Conclusion
  • Implications:
  • Fourth Conclusion
  • Implications:
  • Fifth Conclusion
  • Implications:
  • Sixth Conclusion
  • Implications:
  • Seventh Conclusion
  • Implications:
  • Eighth Conclusion
  • Implications:

APPENDIX A

table of exhibits

Chapter one: Executive Summary

  • Figure 1-1: Incidence of Congestive Heart Failure Cases in the Major World
  • Healthcare Markets: 2007 - 2017
  • Figure 1-2: Prevalence of Congestive Heart Failure Cases in the Major World
  •  Healthcare Markets: 2007 - 2017
  • Table 1-1: The Estimated Markets for Devices Used to Treat CHF in the Major
  • World Healthcare Markets by Geographic Segment
  • Figure 1-3 1Trending in the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment...............................................................................
  • Figure 1-4: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment

CHAPTER  TWO: Overview of Congestive  Heart Failure

  • Table 2-1: International Cardiovascular Disease (CVD) Statistics  
  • Table 2-2: United States CHF Statistics: 2004
  • Table 2-3: CHF Data Sources
  • Table 2-4: Common Contributors to Congestive Heart Failure
  • Figure 2-1: Incidence and Prevalence of Congestive Heart Failure In the World’s Major Healthcare Markets: 2007 - 2017  
  • Figure 2-2: Incidence Rates of Congestive Heart Failure in the Major World
  • Healthcare Markets: 200l - 2017 (Cases per Million Population)
  • Figure 2-3: Prevalence Rates of Congestive Heart Failure in the Major World
  • Healthcare Markets: 2007 - 2017 (Cases per Million Population)
  • Figure 2-4: Percentage Breakdown of Deaths from Cardiovascular Diseases: 2003  
  • Table 2-5: Incidence and Prevalence of CHF in the United States:   2007 - 2017   
  • Figure 2-5: Incidence and Prevalence of CHF in the United States:   2007 - 20017   
  • Figure 2-6: The Distribution of Congestive Heart Failure In the Five Major European Healthcare Markets:  2007
  • Table 2-6: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe:  2007 - 2017  (Thousands)
  • Figure 2-7: Incidence and Prevalence of CHF in the Major Healthcare Markets of Europe:  2007 - 20017 (Thousands)  
  • Table 2-7: Incidence and Prevalence of CHF in Japan:  2007 - 2017
  • Figure 2-8: Incidence and Prevalence of CHF in Japan:  2007 - 20017

CHAPTER THrEE: Device Treatment of Congestive Heart FailURE

  • Table 3-1: Key Implantable Heart Pacing Devices
  • Table 3-2: Vascular Assist Devices
  • Table 3-3: Total Artificial Heart Devices
  • Table 3-4: Facilities Authorized to Performs Total Artificial Heart Implants

CHAPTER FOUR: Congestive Heart Failure Patient Management

  • Figure 4-1: ACC/AHA Guideline Summary for Recommended Therapy of  Congestive Heart Failure by Stage of the Disease
  • Table 4-1: ACC/AHA Staging of Congestive Heart Failure
  • Table 4-2: 2005 ACC/AHA Guidelines for Evaluation and Therapy for Congestive Heart Failure:

CHAPTER FOUR: Congestive Heart Failure MARKETS

  • Table 5-1: The Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment  
  • Figure 5-1: Trending in the Estimated Markets for Devices Used to Treat CHF in the Major World Healthcare Markets by Geographic Segment
  • Figure 5-2: Distribution of the Estimated Markets for Devices Used  to Treat CHF in the Major World Healthcare Markets  by Geographic Segment
  • Table 5-2: The Estimated Markets for Devices Used to Treat CHF in the Major
  • World Healthcare Markets by Device Segment 
  • Figure 5-3: Trending in the Estimated Markets for Devices to Treat CHF in the
  • Major World Healthcare Markets by Device Segment
  • Figure 5-4: Distribution of the Estimated Markets for Devices to Treat CHF in the Major World Healthcare Markets by Device Segment
  • Table 5-3: The Estimated Markets for Devices Used to Treat CHF in the
  • United States Healthcare Market by Device Segment (Pacemakers, ICDs,
  • LVADs, and TAHs)  
  • Figure 5-5: Trending in the Estimated Markets for Devices Used to Treat CHF  in the United States Healthcare Market by Device Segment
  • Figure 5-6: Distribution of the Estimated Markets for Devices Used to Treat
  • CHF in the United States Healthcare Market by Device Segment
  • Table 5-4: The Estimated Markets for Devices Used to Treat CHF in the
  •  Five Major European Healthcare Markets by Device Segment 
  • Figure 5-7: Trending the Estimated Markets for Devices Used to Treat  CHF in the Five Major European Healthcare Markets by  Device Segment
  • Figure 5-8: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Five Major European Healthcare Markets by Device Segment
  • Table 5-5: The Estimated Markets for Devices Used to Treat CHF in the Japanese
  • Healthcare Market by Device Segment 
  • Figure 5-9: Trending in the Estimated Markets for Devices Used to Treat
  • CHF in the Japanese Healthcare Market by Device Segment
  • Figure 5-10: Distribution of the Estimated Markets for Devices Used to Treat CHF in the Japanese Healthcare Market by Device Segment